Experienced in Coronary Heart Disease

Young-keun T. Ahn

Gwangju, KR 
Experienced in Coronary Heart Disease
Gwangju, KR 
OverviewLocationsClinical Research

Overview

Young-keun Ahn practices in Gwangju, Republic of Korea. Ahn is rated as an Experienced expert by MediFind in the treatment of Coronary Heart Disease. Their top areas of expertise are Heart Attack, Coronary Heart Disease, Acute Coronary Syndrome, Low Sodium Level, and Percutaneous Coronary Intervention (PCI).

Their clinical research consists of co-authoring 34 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 7 articles and participated in 7 clinical trials in the study of Coronary Heart Disease.

Locations

Gwangju, Republic of Korea

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Evaluation of Effectiveness and Safety of BIOFREEDOM™ FAMILY Stent in Routine Clinical Practice; A Multicenter, Prospective Observational Study
Evaluation of Effectiveness and Safety of BIOFREEDOM™ FAMILY Stent in Routine Clinical Practice; A Multicenter, Prospective Observational Study
Enrollment Status: Terminated
Publish Date: September 30, 2025
Intervention Type: Device
Comparison of Tailored Antiplatelet Therapy With Early Escalation and Late De-Escalation Strategy Versus Standard Dual Antiplatelet Therapy in Patients Undergoing Complex High-Risk Percutaneous Coronary Intervention
Comparison of Tailored Antiplatelet Therapy With Early Escalation and Late De-Escalation Strategy Versus Standard Dual Antiplatelet Therapy in Patients Undergoing Complex High-Risk Percutaneous Coronary Intervention
Enrollment Status: Completed
Publish Date: June 06, 2025
Intervention Type: Drug
Study Drugs: Tailored antithrombotic strategy, Conventional antithrombotic strategy
Study Phase: Phase 4
Optimal Duration of Antiplatelet Therapy After Bioresorbable Vascular Scaffold Implantation to Reduce Late Coronary Arterial Thrombotic Events: BVS-LATE Trial
Optimal Duration of Antiplatelet Therapy After Bioresorbable Vascular Scaffold Implantation to Reduce Late Coronary Arterial Thrombotic Events: BVS-LATE Trial
Enrollment Status: Completed
Publish Date: June 25, 2024
Intervention Type: Drug
Study Phase: Phase 4
Evaluation of Effectiveness and Safety of Bioresorbable Vascular Scaffold in Routine Clinical Practice; A Multicenter, Prospective Observational Study
Evaluation of Effectiveness and Safety of Bioresorbable Vascular Scaffold in Routine Clinical Practice; A Multicenter, Prospective Observational Study
Enrollment Status: Terminated
Publish Date: December 20, 2023
Intervention Type: Device
Evaluation of Effectiveness and Safety of XIENCE Xpedition/Alpine/Sierra in Routine Clinical Practice; A MULTICENTER, PROSPECTIVE OBSERVATIONAL STUDY
Evaluation of Effectiveness and Safety of XIENCE Xpedition/Alpine/Sierra in Routine Clinical Practice; A MULTICENTER, PROSPECTIVE OBSERVATIONAL STUDY
Enrollment Status: Active_not_recruiting
Publish Date: December 18, 2023
Intervention Type: Device
a Multinational, Multicenter, Prospective, Open-label, Active-treatment-controlled Randomized Trial: Preventive PCI or Medical Therapy Alone for Vulnerable Atherosclerotic Coronary Plaque_PREVENT Trial
a Multinational, Multicenter, Prospective, Open-label, Active-treatment-controlled Randomized Trial: Preventive PCI or Medical Therapy Alone for Vulnerable Atherosclerotic Coronary Plaque_PREVENT Trial
Enrollment Status: Completed
Publish Date: November 18, 2023
Intervention Type: Device, Drug
Study Drug: Optimal Medical treatment
Study Phase: Phase 4
A Multicenter, Prospective, Real World Observational Study for Chronic Total Occlusion
A Multicenter, Prospective, Real World Observational Study for Chronic Total Occlusion
Enrollment Status: Terminated
Publish Date: April 18, 2022
Intervention Type: Procedure, Drug
View 6 Less Clinical Trials

34 Total Publications

Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial.
Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial.
Journal: Lancet (London, England)
Published: February 02, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ahn's expertise for a condition
ConditionClose
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile